Key clinical point: Researchers identified four distinct patient subgroups in severe hemophilia A.
Major finding: Two of the subgroups had Factor VIII inhibitors and two of the subgroups did not.
Study details: The study included 23 infants with previously untreated severe hemophilia A who received 50 days’ exposure to FVIII infusions.
Disclosures: The study is funded by Baxalta, a part of Shire. Dr. Gangadharan is employed by Shire and other authors reported financial disclosures related to the study sponsor.
Gangadharan B et al. ASH 2018, Poster 3774.